Atul Chugh, MD
Cardiovascular Disease · Indianapolis, INNPI 1447463864
Payments from drug & device makers
Across 441 payments — averaging $1756.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$360K
- Merck$118K
- Amarin Pharma, Inc.$82K
- Medtronic$78K
- Boston Scientific$42K
- Angiodynamics, Inc.$40K
- plus $55K from 25 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 42 | $360,122 |
| Merck | 18 | $118,037 |
| Amarin Pharma, Inc. | 78 | $81,538 |
| Medtronic | 141 | $77,601 |
| Boston Scientific | 63 | $41,926 |
| Angiodynamics, Inc. | 10 | $40,112 |
| Regeneron | 17 | $37,277 |
| Biostable Science & Engineering | 6 | $9,952 |
| Idorsia Pharmaceuticals US Inc | 5 | $5,097 |
| Edwards Lifesciences | 8 | $1,082 |
| Cvrx, Inc. | 2 | $302 |
| Heartflow, Inc. | 3 | $216 |
| Pfizer | 10 | $163 |
| E.r. Squibb & Sons, L.L.C. | 5 | $163 |
| Abiomed | 1 | $152 |
| Johnson & Johnson | 3 | $151 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $139 |
| Boehringer Ingelheim | 2 | $132 |
| Lexicon Pharmaceuticals, Inc. | 1 | $126 |
| AstraZeneca | 6 | $95 |
| Novo Nordisk | 4 | $78 |
| Abbott | 2 | $46 |
| Philips North America LLC | 1 | $38 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $33 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Shockwave Medical, Inc | 1 | $14 |
| Bayer | 1 | $14 |
| Kestra Medical Technology Services, Inc. | 1 | $13 |
| Elutia, Inc. | 1 | $13 |
| Amgen | 1 | $12 |
How this compares
$774,670 in reported general payments places this provider in the 95th percentile of 408 cardiovascular disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Indianapolis
- Noel DasguptaIndianapolis$744K
- Vijay RaoIndianapolis$706K
- Roopa RaoIndianapolis$481K
- Julie ClaryIndianapolis$475K
- James TrippiIndianapolis$449K
- John MillerIndianapolis$354K
- Richard KovacsIndianapolis$338K
- David KovacichIndianapolis$327K
- Jose Emanuel FinetIndianapolis$299K
- George LolayIndianapolis$268K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.